𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐞𝐦𝐨𝐬𝐭𝐚𝐬𝐢𝐬 & 𝐓𝐢𝐬𝐬𝐮𝐞 𝐒𝐞𝐚𝐥𝐢𝐧𝐠 𝐀𝐠𝐞𝐧𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬
Overview
Hemostasis is a physiological mechanism that keeps blood fluid by preventing it from leaking out of the body. Hemostasis is defined by the activation of the natural coagulation cascade, which results in the production of clots. Major operations and trauma, on the other hand, result in significant blood loss that cannot be halted by the natural healing process. Hemostats and tissue sealing agents can help in such instances by reducing blood loss and speeding up the healing process. Excessive bleeding during surgical operations can put patients at danger, thus hemostats and tissue sealing agents are becoming more popular. Excessive bleeding can also lead to postoperative problems such as longer surgical procedures and the lack of blood in the body. As a result, preventing such events is critical for favorable patient outcomes and surgical operation efficacy.
The global hemostasis and tissue sealing agents market was worth US$ 3,236.2 million in 2017 and is anticipated to grow at an impressive CAGR of 8.1 percent from 2017 to 2025.
𝐓𝐨 𝐆𝐞𝐭 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 –https://www.coherentmarketinsights.com/insight/request-sample/1567
𝐃𝐫𝐢𝐯𝐞𝐫𝐬
The global hemostasis and tissue sealing agents market is projected to develop considerably as a result of factors such as an increase in the number of surgical operations and a rise in the number of traffic accidents. According to the Health and Social Care Information Centre (HSCIC), surgery is one of the most common treatments provided by the NHS in the U.K., accounting for 4.7 million admissions across a range of locations. The data also shows that between 2004 and 2014, the number of surgical operations grew by 27%. According to the Centers for Disease Control and Prevention (CDC), about 200,000 people died in the United States in 2014 as a result of trauma injuries. An increase in the number of traffic accidents has resulted in severe sports injuries, which is a key element driving demand for the global hemostats and tissue sealing agents market. According to the World Health Organization, more than half of those injured in car accidents were brought to hospitals and had trauma surgery in 2016.
𝐑𝐞𝐬𝐭𝐫𝐚𝐢𝐧𝐭𝐬
The global hemostasis and tissue sealing agents market development is projected to be hampered by the lack of favorable reimbursement policies for hemostat failure in blood loss management, as well as rising surgical treatment costs.
𝐀𝐬𝐤 𝐅𝐨𝐫 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐢𝐧𝐠 𝐓𝐡𝐢𝐬 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.coherentmarketinsights.com/insight/request-discount/1567
𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬
Due to the inclusion of updated technology in new products and intensive research and development, North America is expected to lead the global hemostasis and tissue sealing agents market.
This is due to leading market participants in the region rapidly developing and launching innovative tissue sealing chemicals and solutions. StablePlate RX Canine was released in March 2018 by BodeVet, Inc., a blood-related solutions firm, as the world’s first injectable freeze-dried platelet derived product for the management of pain uncontrolled hemorrhage in cardiac patients.
Due to expanding surgical operations as a result of increased medical tourism in emerging nations like China, Singapore, and India, Asia Pacific is anticipated to rise rapidly throughout the forecast period. The growing frequency of traffic accidents in the Asia Pacific region, which leads to trauma admissions in emergency rooms, is also expected to drive market development in the area during the forecast period. According to the Ministry of Road Transport and Highways of the Indian government, 500,279 people were wounded in road accidents in 2015. These aspects are projected to help the market expand.
𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞
Major market participants are focusing on expanding their footprint in emerging markets by launching new product lines. Baxter International, Inc. finalized the acquisition of two hemostat products from Mallinckrodt in March 2018, and announced the introduction of RECOTHORM and PREVELEAK hemostat sealants in Japan to expand its client base. In order to increase their market share, businesses are also focused on developing novel goods. SURGICEL powdered absorbable hemostat was released in January 2018 by Ethicon LLC, a division of Johnson & Johnson Medical Devices Companies, to help control disruptive bleeding on wide and leaking surfaces.
Major companies contributing in the global hemostasis & tissue sealing agents market are Integra Lifesciences Corporation, Dickinson & Company, Pfizer, Inc., Ethicon LLC, Baxter International, Inc., MIL Laboratories Pvt. Ltd, Cryolife, Inc. Advanced Medical Solutions Group Plc., B. Braun Melsungen AG, Medtronic plc., Cohera Medical, Inc., and Becton.
𝐓𝐨 𝐃𝐢𝐫𝐞𝐜𝐭 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 –https://www.coherentmarketinsights.com/insight/buy-now/1567
𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐒:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837